Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction

Heart

Volumn 91, Issue SUPPL. 2, 2005, Pages

  Cleland, J G F ^a,b   Torabi, A ^b   Khan, N K ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; LOOP DIURETIC AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FIBRINOLYTIC THERAPY; HEALTH SERVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTOLE; UNITED KINGDOM;

ADULT; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 17644406068     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.062026     Document Type: Conference Paper

References (49)

1. Cleland JGF, Clark AL. Delivering the cumulative benefits of triple therapy far heart failure. Too many cooks will spoil the broth. J Am Coll Cardiol 2003;42:1226-33.
2. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41-5.
3. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure in elderly patients with normal versus abnormal left ventricular systolic function associated with coronary artery disease. Am J Cardiol 1990;66:1257-9.
4. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
5. Caruana L, Petrie MC, Davie AP, et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-8.
6. Moller JE, Brendorp B, Ottesen M, et al. Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications. Eur J Heart Failure 2003;5:811-9.
7. Gandhi SK, Powers JC, Nomeir A-M, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22.
8. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus non fatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40%, treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-9.
9. Houghton T, Freemantle N, Cleland JGF. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000;2:333-40.
10. Cleland JG, Huan Loh P, Freemantle N, et al. Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial. Eur J Heart Fail 2004;6:787-91.
11. Cleland JGF. Is aspirin 'The Weakest Link' in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Caradiovsc Dis 2002;44:275-92.
12. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol 1997;12:276-87.
13. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1573.
14. Tunstall-Pedoe H. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA Project populations. Lancet 1999;353:1547-57.
15. Volmink JA, Newton JN, Hicks NR, et al. on behalf of Oxford Myocardial Infarction Incidence Study Group. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. Heart 1998;80:40-4.
16. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-7.
17. Dorsch MF, Lawrance RA, Sapsfard RJ, et al. Poor prognosis of patients presenting with symptomatic myocardial infarction but without chest pain. Heart 2001;86:494-8.
18. Kannel WB, Abbott RD. Incidence and prognosis of unrecognised myocardial infarction: an update on the Framingham Study. N Engl J Med 1984;311:1144-7.
19. Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the global registry of acute coronary events. Chest 2004;126:461-9.
20. Rosamond WD, Folsom AR, Chamless LE, et al. Coronary heart disease trends in four United States communities. The atherosclerosis risk in communities (ARIC) study 1987-1996. Int J Epidemiol 2001;30(suppl 1):S17-22.
21. European Society of Cardiology, American College of Cardiology. Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
22. McKenna CJ, Forfar JC. Was it a heart attack? Troponin positive acute coronary syndrome versus myocardial infarction. BMJ 2002;324:377-8.
23. Kober L, Torp-Pedersen C, Jorgensen S, et al, on behalf of the TRACE study. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. Am J Cardiol 1998;81:1292-7.
24. Hellermann JP, Jacobsen SJ, Reeder GS, et al. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J 2003;145:742-8.
25. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. Eur Heart J 2002;23:1190-201.
26. Kober L, Torp Pedersen C. Clinical characteristics and mortality of patients screened for entry into the trandolapril cardiac evaluation (TRACE) study. Am J Cardiol 1995;76:1-5.
27. Kober L, Torp Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
28. Kober L, Torp-Pedersen C, Pedersen OD, et al, on behalf of the TRACE study group. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996;78:1124-8.
29. Hellermann JP, Jacobsen SJ, Gersh BJ, et al. Heart failure after myocardial infarction. A review. Am J Med 2002;113:324-30.
30. Sufton MSJ, Pfeffer MA, Moye L, et al. for the SAVE Investigators. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Baseline predictors and impact of long-term use of captopril: information from the survival and ventricular enlargement (SAVE) trial. Circulation 1997;96:3294-9.
31. Christian TF, Gitter MJ, Miller TD, et al. Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size. J Am Coll Cardiol 1997;30:1633-40.
32. Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Int Med 2001;134:451-8.
33. Roger VI, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50.
34. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction. The Framingham heart study. Circulation 1999;100:2054-9.
35. Hellermann JP, Goraya TY, Jacobsen SJ, et al. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol 2003;157:1101-7.
36. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. The National Registry of Myocardial Infarction. Circulation 2002;105:2605-10.
37. Richards AM, Nicholls MG, Yandle TG, et al, The Christchurch Cardioendocrine Research Group. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999;81:114-20.
38. James SK, Lindahl B, Siegbahn A, et al. N-Terminal pro-brain natriuretic peptide and other risk markers far the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
39. Hellermann JP, Jacobsen SJ, Redfield MM, et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Failure 2005;7:119-25.
40. Mosterd A, Deckers JW, Hoes AW, et al. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol 1997;13:491-502.
41. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
42. Pfeffer MA, Braunwald E, Moye IA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
43. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
44. Dargie HJ, The CAPRICORN Steering Committee. Design and methodology of the CAPRICORN trial - a randomised double-blind, placebo-controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dsyfunction after myocardial infarction. Eur J Heart Failure 2000;2:325-32.
45. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
46. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
47. Velazquez EJ, Pfeffer MA, McMurray JJV, et al. Valsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context. Eur J Heart Fall 2003;5:537-44.
48. Torp-Pedersen C, Kober L, for the TRACE study group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reducea left ventricular function after acute myocardial infarction. TRACE study group. Lancet 1999;354:9-12.
49. Murphy NF, MacIntyre K, Capewell S, et al. Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis. BMJ 2004;328:1413-4.